PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer - Concepedia

Concepedia

Publication | Open Access

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

DOI Full Paper Access

332

Citations

21

References

2021

Year

Yoon‐Koo Kang, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young‐Woo Kim, Jin Young Kim, Min‐Hee Ryu, Sun Young Rha, Ik‐Joo Chung, In‐Ho Kim,

Journal of Clinical Oncology

Abstract

PRODIGY showed that neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, is effective and tolerable in Korean patients with LAGC.

References

	Year	Citations

Page 1